Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edurne Arriola

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
BMC Cancer|February 1, 2018
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in SpainEdurne Arriola, Ramón García Gómez, Pilar Diz, et al.
Translational Lung Cancer Research|May 19, 2025
Prevalence of <i>EGFR</i> gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN studyMar Varela, Cristina Teixidó, Carlos Álvarez-Fernández, et al.
Frontiers in Oncology|November 6, 2023
Comprehensive NGS profiling to enable detection of <i>ALK</i> gene rearrangements and <i>MET</i> amplifications in non-small cell lung cancerSergi Clavé, Jennifer B Jackson, Marta Salido, et al.
Frontiers in Oncology|January 1, 2025
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter studyAida Piedra, Sergio Martínez-Recio, Ainhoa Hernández, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerBenjamin B Morris, Simon Heeke, Yuanxin Xi, et al.
Molecular Cancer|March 21, 2025
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerBenjamin B Morris, Simon Heeke, Yuanxin Xi, et al.
Plos One|September 24, 2014
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistryEsther Conde, Ana Suárez-Gauthier, Amparo Benito, et al.
Lung Cancer (Amsterdam, Netherlands)|June 1, 2023
Pre-existing tumor host immunity characterization in resected non-small cell lung cancerPedro Rocha, Maite Rodrigo, Laura Moliner, et al.
The New England Journal of Medicine|October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
Frontiers in Artificial Intelligence|May 6, 2026
Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLCPedro Rocha, Joan Gibert, Silvía Menendez, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
BMC Cancer|February 1, 2018
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in SpainEdurne Arriola, Ramón García Gómez, Pilar Diz, et al.
Translational Lung Cancer Research|May 19, 2025
Prevalence of <i>EGFR</i> gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN studyMar Varela, Cristina Teixidó, Carlos Álvarez-Fernández, et al.
Frontiers in Oncology|November 6, 2023
Comprehensive NGS profiling to enable detection of <i>ALK</i> gene rearrangements and <i>MET</i> amplifications in non-small cell lung cancerSergi Clavé, Jennifer B Jackson, Marta Salido, et al.
Frontiers in Oncology|January 1, 2025
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter studyAida Piedra, Sergio Martínez-Recio, Ainhoa Hernández, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerBenjamin B Morris, Simon Heeke, Yuanxin Xi, et al.
Molecular Cancer|March 21, 2025
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerBenjamin B Morris, Simon Heeke, Yuanxin Xi, et al.
Plos One|September 24, 2014
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistryEsther Conde, Ana Suárez-Gauthier, Amparo Benito, et al.
Lung Cancer (Amsterdam, Netherlands)|June 1, 2023
Pre-existing tumor host immunity characterization in resected non-small cell lung cancerPedro Rocha, Maite Rodrigo, Laura Moliner, et al.
The New England Journal of Medicine|October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Benjamin Solomon, Herbert H Loong, et al.
Frontiers in Artificial Intelligence|May 6, 2026
Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLCPedro Rocha, Joan Gibert, Silvía Menendez, et al.
Pageof 9